How To Save A Life: CV Therapeutics Revamps R&D, Ranexa Sales Focus
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm says it will seek a partner to help detail Ranexa to internal medicine and primary care physicians if granted FDA approval for expanded labeling based on MERLIN results.
You may also be interested in...
CV Therapeutics’ Ranexa Grows In Fourth Quarter; Partner Talks Continue
New heart indication, diabetes could be next, as pendulum swings to company’s favor, analyst tells “The Pink Sheet” DAILY.
CV Therapeutics’ Ranexa Grows In Fourth Quarter; Partner Talks Continue
New heart indication, diabetes could be next, as pendulum swings to company’s favor, analyst tells “The Pink Sheet” DAILY.
CV Therapeutics Seeks Ranexa Labeling Changes Based on MERLIN Study
sNDA includes new analysis of MERLIN-TIMI 36 data, which should eliminate safety concerns around QTc prolongation, clinical researchers report at the European Society of Cardiology.